Telix Pharmaceuticals has announced that the first patient has been dosed in a trial in China to test its PET radiotracer injection kit Illuccix for prostate cancer imaging.
Illuccix is a kit for preparing gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 PET radiotracer injections in patients with advanced prostate cancer. The study is required to establish that the diagnostic utility of Illuccix is equivalent in Chinese and Western populations. Illuccix was cleared by the U.S. Food and Drug Administration in March.
The study will enroll up to 110 patients with relapsed prostate cancer, with data to support a future marketing authorization application for the kit in China, Telix added.